| Examining treatment of ST-elevation myocardial infarction: the importance of early intervention. | |
| | |
MedLine Citation:
|
PMID: 20061507 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Early reperfusion in ST-segment elevation myocardial infarction (STEMI) is imperative. Acute reperfusion may be achieved with fibrinolytic agents and/or percutaneous coronary intervention (PCI); however, PCI is associated with lower rates of death and myocardial infarction compared with fibrinolysis. As treatment delays are associated with worse outcomes, current guidelines recommend minimizing time from symptom onset to treatment initiation. Regardless of the reperfusion strategy, patients with STEMI are at increased risk of early recurrent ischemic events and death. These risks can be significantly reduced by promptly initiating a combination of pharmacotherapies that includes antiplatelet and anticoagulant agents, beta-blockers, and inhibitors of the renin-angiotensin-aldosterone system. This manuscript reviews the evidence supporting the most recent guidelines for STEMI management published jointly by the American College of Cardiology and American Heart Association. More recent evidence and its potential impact on future evidence-based guidelines are also addressed. |
| | |
Authors:
|
Gervasio A Lamas; Esteban Escolar; David P Faxon |
Related Documents
:
|
23638067 - Loss of pink1 increases the heart's vulnerability to ischemia-reperfusion injury. 23074627 - Pharmacological and nonpharmacological prevention of atrial fibrillation after coronary... 11228087 - Refractory no-reflow successfully treated with local infusion of high-dose adenosine an... 23449547 - Rotors and the dynamics of cardiac fibrillation. 19576337 - Relation between inheritance of cyanotic congenital heart disease and persistent forame... 16138237 - Mitral valve annuloplasty with a bovine pericardial strip--18-year results. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2010-01-08 |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology and therapeutics Volume: 15 ISSN: 1940-4034 ISO Abbreviation: J. Cardiovasc. Pharmacol. Ther. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-05 Completed Date: 2010-04-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9602617 Medline TA: J Cardiovasc Pharmacol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 6-16 Citation Subset: IM |
Affiliation:
|
Columbia University Division of Cardiology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA. srosenho@msmc.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome Adrenergic beta-Antagonists / therapeutic use Fibrinolytic Agents / therapeutic use* Humans Myocardial Infarction / therapy* Myocardial Reperfusion / methods* Platelet Aggregation Inhibitors / therapeutic use Practice Guidelines as Topic Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Microbacterium radiodurans sp. nov., a UV radiation-resistant bacterium isolated from soil.
Next Document: The Falls Efficacy Scale International (FES-I). A comprehensive longitudinal validation study.